Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD – has no relevant financial relationships to disclose in relation to the content of this activity.
Joan B. Fowler, PharmD, BCPP – has no relevant financial relationships to disclose in relation to the content of this activity.
Mollie E. Moran, MSN, CNP, AOCNP® – has no relevant financial relationships to disclose in relation to the content of this activity.
Susan H. Scher, MD – has no relevant financial relationships to disclose in relation to the content of this activity.
Jennifer A. Woyach, MD – has disclosed that she receives grant/research support from Abbvie, Karyopharm, and MorphoSys.

Presenters:
John N. Allan, MD – has disclosed that he is a consultant for Abbvie, Genentech, Pharmacyclics, and Verastem.
Danielle M. Brander, MD – has disclosed that she is a consultant for Abbvie, Genentech, Pharmacyclics, T6 Therapeutics, and Teva. She receives other financial/material support from the Novartis.
Matthew S. Davids, MD, MMSc – has disclosed that he is a consultant for Abbvie, AstraZeneca, Celgene, Genentech, Janssen, Merck, MEI Pharma, and Pharmacyclics. He also receives grant/research support from Bristol-Myers Squibb, Genentech, Pharmacyclics, Surface Oncology, and TG Therapeutics.
Brian T. Hill, MD, PhD – has disclosed that he receives grant/research support from Abbvie and Pharmacyclics.
Javier Pinilla-Ibarz, MD, PhD-has disclosed that he is a consultant for Abbvie, Gilead, Janssen, Novartis, Pfizer, and Pharmacyclics. He also is a member of the speakers’ bureaus for Abbvie, Gilead, and Pharmacyclics.
Nina Wagner-Johnston, MD-has disclosed that she is a consultant for ADC Therapeutics, Janssen, and Juno.
Loretta J. Nastoupil, MD-has disclosed that she is a consultant for Celgene, Genentech, Gilead, and Merck.
Kerry Rogers, MD – has disclosed that she receives grant/research support from Genentech.
Stephen E. Spurgeon, MD – has disclosed that he is a consultant for Gilead and Pharmacyclics. He also receives grant/research support Acerta, AstraZeneca, Bristol-Myers Squibb, and Genentech.
Jennifer A. Woyach, MD -has disclosed that she receives grant/research support from Abbvie, Karyopharm, and MorphoSys.